Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP)

Federman & Sherwood Investigates Salix Pharmaceuticals, Ltd. for Possible Violations of Federal Securities Laws

 

Oklahoma City, OK (November 7, 2014) – The law firm of Federman & Sherwood has launched an investigation into Salix Pharmaceuticals, Ltd. [NASDAQ: SLXP] (“Salix”) for possible violations of federal securities laws.

 

On November 6, 2014 Salix announced disappointing financial results for the third quarter 2014 which included an $88.6 million net loss.  Salix also announced the resignation of Adam Derbyshire as its chief financial officer.  Early reports indicate that Mr. Derbyshire’s resignation was related to an accounting scandal involving levels of key gastrointestinal drugs, forcing a reduction in Salix’s financial forecasts for the remainder of the year.  On this news, Salix’s shares fell $50.33 per share to $88.22 per share in after-hours trading.

If you currently own securities in Salix Pharmaceuticals, Ltd. and purchased your shares prior to November 7, 2014, have information to assist in our investigation, or want to be considered as a plaintiff in future litigation, please click here to download and complete our Investor Certification.  Once completed, please email the Investor Certification form to rkh@federmanlaw.com, fax to (405) 239-2112 or send by regular mail to:  Federman & Sherwood, Attn:  Robin, 10205 North Pennsylvania Avenue, Oklahoma City, OK  73120.  If you have any questions regarding this investigation, please contact William B. Federman. Federman & Sherwood has extensive nationwide experience in representing investors in securities, derivative and merger-related shareholder class actions, and has been appointed as lead counsel in multiple complex cases.

Copyright © 2017 Federman & Sherwood. All Rights Reserved.